P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

Blaquier, Juan Bautista; Cerini, M.; Denninghoff, Valeria; Jauk, Federico; Wainsztein, V.; Basbus, Luis; Dalurzo, Liliana; Romano, V.; Lupinacci, L.; Rivello, Hernán Garcı́a; Minatta, J.N.; Recondo, Gonzálo

doi:10.1016/j.jtho.2021.01.1247

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be related to the tendency of endocrine differentiation in some NSCLC; thus, it has an ordinary sensitivity and specificity. ProGRP was significantly elevated in BALF, which has a certain value for clinical diagnosis of lung cancer [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs

Tian

Qin

2022

BioMed Research International

View full text Add to dashboard Cite

Background. Lung cancer is a common clinical thoracic malignant tumor, which had a serious impact on the safety of patients, currently ranking first in all malignant tumors in morbidity and mortality, with generally less than 5% survival rate in 5 years. Objective. To investigate the relationship and significance between carcinoembryonic antigen (CEA) and precursor gastrin-releasing peptide (ProGRP) changing levels in bronchoalveolar lavage fluid (BALF) and CT imaging features in patients with peripheral lung cancer. Methods. A total of 90 patients diagnosed with peripheral lung cancer as the lung cancer group and 60 patients with benign lung diseases as the control group in our hospital from May 2019 to October 2021 were selected to compare the differences of CEA and ProGRP in BALF by the classification of CT features. Results. The levels of CEA and ProGRP in the BALF of the lung cancer group were significantly higher than those of the control group; the proportion of patients with lobulation sign, burr sign, ground glass sign, pleural effusion, and lesion diameter ≥ 3.0 cm in the lung cancer group was higher than that in the control group; the CEA level in BALF of lung cancer patients with spicule sign, pleural effusion, and lesion diameter ≥ 3.0 cm was significantly higher than that without these symptoms, while ProGRP level in the BALF of lung cancer patients with lobulation sign, burr sign, ground glass sign, pleural effusion, and lesion diameter ≥ 3 . 0 cm was significantly higher than that of lung cancer patients without these symptoms. Conclusion. The check of CEA and ProGRP in BALF in combination with CT features has a certain clinical value for the diagnosis of lung cancer. At the same time, the increased levels of CEA and ProGRP in BALF have a certain correlation with the changes of malignant signs of lung cancer in CT examination.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs

Tian

Qin

2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Analysis of clinical and pathologic data from two academic centers in Buenos Aires suggests that KRAS mutations occur in approximately 23% of patients with NSCLC, a higher frequency than that reported across Latin America. 175 There was a higher proportion of male patients (65%) and smoking history (94%); mean patient age was 66 years (IQR: 61-72.5 years). In total, 94% of tumor histology samples were identified as adenocarcinoma.…”

Section: Argentinamentioning

confidence: 92%

“…With a follow-up of 38 months, median OS of patients with metastatic disease was 14.2 months (95% confidence interval [CI], 7.7-30.3). 175 When considering uncommon EGFR mutations (other than L858R and exon 19 deletion), distribution of tumors comprised exon 18 G719X (46.7%), exon 21 L861Q (24.4%), exon 20 T790M (20%), exon 20 S768I (11.1%), exon 20 insertion (4.4%), and exon 19 pLys745_Ala750del (2.2%). 174 Among patients included in the database review, the most frequent EGFR TKI regimen received was afatinib, followed by erlotinib/gefitinib, and osimertinib.…”

Section: Argentinamentioning

confidence: 99%

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo¹,

Avilés‐Salas²,

Soares³

et al. 2021

OTT

View full text Add to dashboard Cite

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. The presence of these mutations is predictive of response to targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs) and ALK TKIs. However, there are substantial challenges for the implementation of biomarker testing, particularly in emerging countries. Understanding the barriers to testing in NSCLC will be key to improving molecular testing rates worldwide and patient outcomes as a result. In this article, we review EGFR mutations and ALK rearrangements as predictive biomarkers for NSCLC, discuss a selection of appropriate tests and review the literature with respect to the global uptake of EGFR and ALK testing. To help improve testing rates and unify procedures, we review our experiences with biomarker testing in China, South Korea, Russia, Turkey, Brazil, Argentina and Mexico, and propose a set of recommendations that pathologists from emerging countries can apply to assist with the diagnosis of NSCLC.

show abstract

“…In Brazil, the reported prevalence of KRAS mutations is 24.2% and 23% in Argentina. 50 , 58 In the case of ALK fusions, there are no significant differences in the reported prevalence in the region, ranging from 3.7% in Chile to 9.5% in Costa Rica. 50 , 59 , 60 …”

Section: Lung Cancer In Americamentioning

confidence: 97%

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

Laguna,

García-Pardo,

Alessi

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Lung cancer poses a global health challenge and stands as the leading cause of cancer-related deaths worldwide. However, its incidence, mortality, and characteristics are not uniform across all regions worldwide. Understanding the factors contributing to this diversity is crucial in a prevalent disease where most cases are diagnosed in advanced stages. Hence, prevention and early diagnosis emerge as the most efficient strategies to enhance outcomes. In Western societies, tobacco consumption constitutes the primary risk factor for lung cancer, accounting for up to 90% of cases. In other geographic locations, different significant factors play a fundamental role in disease development, such as individual genetic predisposition, or exposure to other carcinogens such as radon gas, environmental pollution, occupational exposures, or specific infectious diseases. Comprehensive clinical and molecular characterization of lung cancer in recent decades has enabled us to distinguish different subtypes of lung cancer with distinct phenotypes, genotypes, immunogenicity, treatment responses, and survival rates. The ultimate goal is to prevent and individualize lung cancer management in each community and improve patient outcomes.

show abstract

P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

Abstract: expected to take 35 months. Conclusion: We conduct a phase II study to investigate the safety and efficacy of nivolumab combined with anlotinib in advanced non-small cell lung cancer patients previously treated with checkpoint inhibitors.

Cited by 5 publications

References 0 publications

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

Contact Info

Product

Resources

About